Precision medicine has led to the development of targeted therapies that specifically address the molecular characteristics of a patient's tumor. Drugs like PARP inhibitors are used for patients with BRCA mutations in ovarian cancer. These therapies offer the potential for more effective treatment with fewer side effects compared to traditional chemotherapy.
